Drug-eluting stents: the beginning of the end of restenosis?
In multiple clinical trials, patients who received drug-eluting stents instead of plain stents during percutaneous coronary interventions had rates of restenosis that were lower by roughly one half to three fourths, depending on how restenosis was defined and on the population studied. These stents will likely be used more and more as their indications evolve.
Haery
Cameron
C
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Sachar
Ravish
R
Ellis
Stephen G
SG
D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000517:prevention & control*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D032389:Myocytes, Smooth Muscle / Q000187:drug effects; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology; D020123:Sirolimus / Q000008:administration & dosage* / Q000494:pharmacology; D015607:Stents
D004337:Drug Carriers; D017239:Paclitaxel; D020123:Sirolimus